The 36-month beta value for ONCY is at 1.94. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ONCY is 70.52M, and currently, shorts hold a 1.30% of that float. The average trading volume for ONCY on April 04, 2024 was 392.65K shares.
ONCY) stock’s latest price update
The stock price of Oncolytics Biotech, Inc. (NASDAQ: ONCY) has jumped by 9.09 compared to previous close of 1.10. Despite this, the company has seen a gain of 16.50% in its stock price over the last five trading days. PRNewsWire reported 2024-03-04 that Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, March 4, 2024 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m.
ONCY’s Market Performance
Oncolytics Biotech, Inc. (ONCY) has seen a 16.50% rise in stock performance for the week, with a 16.50% gain in the past month and a -9.43% plunge in the past quarter. The volatility ratio for the week is 4.40%, and the volatility levels for the past 30 days are at 4.88% for ONCY. The simple moving average for the past 20 days is 15.56% for ONCY’s stock, with a -30.99% simple moving average for the past 200 days.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at 11.41% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.65% of loss for the given period.
Volatility was left at 4.88%, however, over the last 30 days, the volatility rate increased by 4.40%, as shares surge +18.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, ONCY rose by +19.42%, which changed the moving average for the period of 200-days by -36.27% in comparison to the 20-day moving average, which settled at $1.0479. In addition, Oncolytics Biotech, Inc. saw -11.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONCY
The total capital return value is set at -0.98. Equity return is now at value -101.82, with -72.28 for asset returns.
Based on Oncolytics Biotech, Inc. (ONCY), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -67.25. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 113.77.
Currently, EBITDA for the company is -33.39 million with net debt to EBITDA at 0.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.01.
Conclusion
In conclusion, Oncolytics Biotech, Inc. (ONCY) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
